Hematology

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.

Imetelstat (Rytelo; Geron) significantly improved and sustained health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), with benefits linked directly to the drug rather than patient characteristics.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.

Carrie Kitko, MD, explains that axatilimab maintains strong response rates in patients with chronic graft-versus-host disease (GVHD) regardless of previous treatment lines and emphasizes the need to explore combination therapies.

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of life and emotional well-being.

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.